ALL Therapeutics

Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia

Individuals with Down syndrome (DS) are 20 times more vulnerable...

Challenges and future directions for access to cell therapies: A global perspective

This overview of perspectives from various regions summarizes different challenges that hematologists and patients...

Blinatumomab injection approved in China for pediatric relapsed or refractory CD19+ B-cell precursor acute lymphoblastic leukemia

On May 4, 2022, it was announced that blinatumomab for injection...

Sequential treatment with blinatumomab and inotuzumab in patients with relapsed B-ALL

In comparison to conventional chemotherapy, both blinatumomab and inotuzumab show superior antileukemic activity...

Frontline ponatinib with steroids for patients with Ph+ ALL

The ALL Hub is pleased to present a visual abstract representing key data from the phase II INCB84344-201 trial (NCT01641107) evaluating...

Why are novel TKIs needed for Ph+ ALL? What does this mean for patients?

During the 63rd ASH Annual Meeting and Exposition, the ALL Hub was pleased to speak with Jorge Cortes, Augusta University,...

Eryaspase for ALL: Results from the NOR-GRASPALL-2016 study

When combined with chemotherapy, eryaspase demonstrated a favorable tolerability profile; two of the 55 enrolled patients withdrew treatment...

Healthcare inequalities in bone marrow transplants

Examining different treatment and diagnostic options for patients undergoing bone marrow transplant (BMT) is an important part of improving outcomes....